&nbsp;

Oct 2024

Regimen

PEMB

Cancer Type:

Lung,

Non-Small Cell

Intent: Adjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Adjuvant Treatment for Non-Small Cell Lung Cancer

Drugs Used:

pembrolizumab

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

PEMB

Cancer Type:

Breast,

Central Nervous System,

Endocrine,

Adrenal,

Neuroendocrine,

Pancreatic Neuroendocrine,

Parathyroid,

Thymoma,

Thyroid,

Gastrointestinal,

Anus,

Colorectal,

Esophagus,

Gastric / Stomach,

Gastrointestinal Stromal Tumours,

Hepatobiliary / Liver / Bile Duct,

Mesothelioma (Peritoneal),

Neuroendocrine (GI),

Pancreas,

Rectal,

Small bowel and appendix,

Genitourinary,

Bladder / Urothelial,

Penile,

Prostate,

Renal cell / Kidney,

Testis,

Gynecologic,

Cervix,

Endometrial,

Germ Cell,

Gestational Trophoblastic Disease,

Ovary,

Uterine Sarcoma,

Vagina,

Vulva,

Head and Neck,

Larynx,

Nasopharynx,

Oral,

Paranasal Sinus,

Pharynx,

Salivary Gland,

Squamous Cell,

Kaposi's Sarcoma,

Lung,

Mesothelioma (Pleural),

Neuroendocrine (Lung),

Non-Small Cell,

Small Cell,

Mesothelioma,

Ocular / Eye,

Sarcoma,

Desmoid Tumour,

Ewing's,

Ewing's and Soft Tissue,

GIST,

Giant Cell Tumour,

Kaposi's Sarcoma,

Osteogenic / Bone,

Soft Tissue,

Uterine,

Wilm's Tumour,

Skin,

Basal Cell,

Melanoma,

Merkel Cell,

Squamous Cell,

Unknown Primary

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab (Adult and Pediatric) - Unresectable or Metastatic MSI-H or dMMR Advanced Solid Tumours

Drugs Used:

pembrolizumab

Quick Link(s):

Regimen Monograph

Jun 2025

Drug

pembrolizumab

Other Name(s): Keytruda®

Quick Link(s):

Jun 2025

Drug

niraparib / abiraterone

Other Name(s): Akeega™

Quick Link(s):

Updated

Jul 2025

Guidelines and Advice

Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer

Status: Current
ID: GL 17-10 v2
Version: 2

Updated

Mar 2025

Drug

niLOtinib

Other Name(s): Tasigna®

Quick Link(s):

Updated

Jul 2025

Regimen

NILO

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

niLOtinib - Chronic phase Ph+ CML, with specific criteria

Exceptional Access Program

niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria

Drugs Used:

niLOtinib

Quick Link(s):

Regimen Monograph

Updated

Jul 2025

Regimen

NIVL+IPIL

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Drugs Used:

nivolumab (Unfunded),

ipilimumab (Unfunded)